Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Real-world evidence to guide healthcare policies in oncology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phospho-ERK levels as predictors for chemotherapy of rectal carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Single mRNP Analysis Reveals that Small Cytoplasmic mRNP Granules Represent mRNA Singletons

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Trends in oncological phase I trials

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Purpose: We evaluated longitudinal tracking of BRAF V600E in circulating cell-free DNA (cfDNA) as a marker of treatment response to BRAF inhibitor (BRAFi) combination therapies in non-melanoma solid tumors included in the Copenhagen Prospective Personalized Oncology (CoPPO) program.

Experimental design: Patients with BRAF V600E-mutated tumors were treated with combination therapies including BRAFi. Quantification of mutant cfDNA from plasma was determined and correlated to clinical outcomes. Exome sequencing was performed to identify possible resistance mutations.

Results: Twenty-three patients had BRAF-mutated tumors out of 455 patients included in CoPPO and 17 started BRAFi combination (EGFRi/MEKi) therapy. Tumor responses were achieved in 8 out of 16 evaluable patients and the median overall- and progression-free survival (OS and PFS) was 15 and 4.8 months, respectively. Longitudinal measurements of BRAF V600E-mutant cfDNA indicated disease progression prior to radiological evaluation and a reduction in the mutant fraction of more than 50% after 4 and 12 weeks of therapy was associated with a significantly longer PFS (p=0.003 and p=0.029) and OS (p=0.029 and p=0.017). Furthermore, the baseline mutant fraction and total level of cfDNA positively correlated with tumor burden (p=0.026 and p=0.024). Finally, analysis of cfDNA at progression revealed novel mutations potentially affecting the MAPK pathway.

Conclusion: BRAFi combination therapies showed a response rate of 50% in BRAF V600E-mutated non-melanoma tumors. The fraction of BRAF-mutant cfDNA represent a sensitive indicator for clinical outcomes with plasma collected at week 4 and 12 as crucial time points for monitoring response and disease progression.

Original languageEnglish
JournalOncotarget
Volume9
Issue number66
Pages (from-to)32570-32579
Number of pages10
ISSN1949-2553
DOIs
Publication statusPublished - 24 Aug 2018

ID: 55864806